|
TRIAL NAME
|
Registered
(Y/N)
|
ACTR Number
|
Date of Registration
|
|
ANZMTG
|
|
|
|
|
ANZMTG RP01.09 - Improving Quality of Life (QOL) measurement for melanoma patients and their families: Validity and reliability study of QOL instruments in an Australian sample (Acronym: MEL-QOL
|
Y
|
ACTRN12609000344291
|
25/05/2009
|
|
ANZMTG 02.09 - Assessing the feasibility, safety and toxicity of vitamin D following primary treatment of melanoma at high risk of recurrence: A pilot placebo controlled randomised phase II trial (Acronym: Mel-D)
|
Y
|
ACTRN12609000351213
|
25/05/2009
|
|
ANZMTG 01.07 - Whole Brain Radiotherapy (WBRT) following local treatment of intracranial metastases of melanoma - A randomised phase III trial
(Acronym: WBRT in melanoma)
|
Y
|
ACTRN12607000512426
|
9/10/2007
|
|
ANZMTG 01.09 - A Randomised Trial of Post-Operative Radiation Therapy Following Wide Excision of Neurotropic Melanoma of the Head and Neck (Acronym: RTN2)
|
The trial is listed on clinicaltrials.gov but not yet on ANZCTR-pending (TROG to progress).
|
|
|
|
A phase III multicenter randomized trial of sentinel lymphadenectomy and complete lymph node dissection versus sentinel lymphadenectomy alone, in cutaneous melanoma patients with molecular or histopathological evidence of metastases in the sentinel node(Acronym: MSLT II)
|
Y
|
ACTRN12606000347561
|
25/11/2004
|
|
ANZMTG 01.02 - A randomised clinical trial of surgery versus surgery plus adjuvant radiotherapy for regional control in patients with completely resected macroscopic nodal metastatic melanoma
|
Y
|
ACTRN12607000063415
|
23/12/2003
|
|
A clinical study of wide excision alone versus wide excision with intraoperative lymphatic mapping and Sentinel Lymph Node Dissection in the treatment of patients with cutaneous invasive melanoma
(Acronym: MSLT I)
|
N – Recruited prior to ANZCTR register
|
|
|
|
ALTG
|
|
|
|
|
ALTG 04/003 - MATES: Maintenance Thalidomide in Mesothelioma Patients. A phase III trial of anti-angiogenic agent Thalidomide in patients with malignant pleural mesothelioma after first line chemotherapy.
|
Y
|
ACTRN12609000141246
|
Don’t Know
|
|
ALTG 04/008 - ANTS Trial (Australian Neoadjuvant Therapy Study for Non-small Cell Lung Cancer). A randomised phase II study comparing cisplatin and docetaxel with or without cetuximab given as neoadjuvant therapy in patients with stage II and IIIA resectable non-small cell lung cancer.
|
Y
|
ACTRN12608000061336
|
Don’t Know
|
|
ALTG 06/003 - NITRO: A Phase III, randomised trial of adding nitroglycerin to first line chemotherapy for advanced non-small cell lung cancer
|
Y
|
ACTRN12608000588392
|
Don’t Know
|
|
ALTG 08/001 - PA in Lung: The impact of physical activity on quality of life in patients with thoracic cancer
|
N
|
Concept In development – pilot study being done at the moment
|
N/A
|
|
ALTG 08/002 - IPI926: Phase II trial of IPI926 in Small Cell Lung Cancer
|
N
|
Concept In development
|
N/A
|
|
ALTG 09/001 - BR.29. A double blind randomised trial of cediranib versus placebo in patients receiving paclitaxel/carboplatin chemotherapy for the treatment of advanced or metastatic non-small cell lung cancer.
|
Y
|
ACTRN12609000247279
|
Don’t Know
|
|
ALTG 09/002 - BR26: The BR26 trial is a 2-stage, phase III, placebo controlled trial of a new irreversible EGFR inhibitor (PF-804) in patients with advanced non-small cell lung cancer who are PS 0-3, have completed first or second line chemo and have progressed after either erlotinib or gefitinib.
|
N
|
Concept In development
|
N/A
|
|
ANZBCTG
|
|
|
|
|
ANZ 0802 / CIRG/TORI 012 - A phase III study of IMC-1121B plus Docetaxel versus placebo plus Docetaxel in previously untreated patients with HER2-negative, unresectable, locally-recurrent or metastatic breast cancer.
|
Y
|
NCT00703326
EUDRACT No. 2008-001727-65
|
|
|
ANZ 0702 (ALTTO) - A phase III study of adjuvant lapatinib, trastuzumab, their sequence and their combination in patients with HER2/ErbB2 positive primary breast cancer.
|
Y
|
ACTRN12609000208202
|
|
|
ANZ 0701 (Co-SOFT) - A substudy to the SOFT trial which evaluates the cognitive function of premenopausal women with endocrine responsive breast cancer participating in SOFT.
|
Y
|
ACTRN12607000542493
|
|
|
ANZ 0601 / CIRG/TORI 010 - A phase II trial of double-blind, placebo controlled AMG 706 in combination with paclitaxel, or open-label bevacizumab in combination with paclitaxel, as first line therapy in women with HER2 negative locally recurrent or metastatic breast cancer.
|
Y
|
ACTRN12606000507583
|
|
|
ANZ 0501/LATER - Later adjuvant Aromatase inhibitor Therapy for postmenopausal women with Endocrine Responsive tumour.
|
Y
|
ACTRN12607000137493
|
|
|
ANZ 0502 - A phase II trial evaluating the efficacy and safety of epirubicin and cyclophosphamide followed by docetaxel with gemcitabine (+ trastuzumab if HER2 Positive) as neoadjuvant chemotherapy for women with large operable or locally advanced breast carcinoma including inflammatory breast cancer.
|
Y
|
ACTRN12606000191594
|
|
|
ANZ 0301 / BCIRG 103 (1839 IL / 0219) - Presurgical Study Evaluating IRESSA.
|
Y
|
ACTRN12607000013460
|
|
|
ANZ 0201 (TIBER) – Phase II trial of IRESSA in patients with hormone insensitive or hormone resistant metastatic or inoperable locally advanced breast cancer.
|
Y
|
ACTRN12605000477628
|
|
|
ANZ 02P2 / IBIS-II (prevention) – Trial to determine if anastrozole (Arimidex) is effective in preventing breast cancer in postmenopausal women at increased risk of the disease.
|
Y
|
ACTRN12605000216617
|
|
|
ANZ 02P2 / IBIS-II DCIS
|
Y
|
ACTRN12605000282684
|
|
|
ANZ 02P2 / IBIS-II Bone sub-protocol
|
Y
|
ACTRN12605000222640
|
|
|
ANZ 0101 / BIG 1-01 - A phase II trial comparing 1 year and 2 years of Herceptin, versus no Herceptin in women with HER2-positive primary breast cancer who have completed adjuvant chemotherapy.
|
Y
|
ACTRN12607000011482
|
|
|
ANZ 0102 / BCIRG 007 - Trial to evaluate Taxotere® and Herceptin® Vs Taxotere®, Carboplatin and Herceptin® as First Line Chemotherapy in Metastatic Breast Cancer patients containing the Her2 Gene Amplification.
|
Y
|
ACTRN12607000032459
|
|
|
ANZ 0001 - Capecitabine vs CMF in Advanced Breast Cancer
|
Y
|
ACTRN12606000379516
|
|
|
ANZ 9801 / ATAC - Arimidex, Tamoxifen, Alone or in Combination.
|
Y
|
ACTRN12606000527561
|
|
|
ANZ 9602 (ATLAS) - Adjuvant tamoxifen longer against shorter (ATLAS) clinical trial in early breast cancer. Reliable assessment of the efficacy and safety of prolonging the use of adjuvant tamoxifen: a large, simple, randomised study.
|
Y
|
ACTRN12606000533594
|
|
|
ANZ 9311 - Phase III trial to compare the effect of a short high dose intensive course of chemotherapy with filgrastim support versus a conventional standard dose course of chemotherapy in patients with advanced breast cancer.
|
Y
|
ACTRN12605000478617
|
|
|
ANZ 92P1 / IBIS-I - Trial designed to determine whether women at high risk of developing breast cancer can avoid breast cancer if they use tamoxifen.
|
Y
|
ISRCTN91879928
|
|
|
ANZ 9002 - Protocol for the management of screen detected ductal carcinoma in situ (DCIS) of the breast.
|
Y
|
ACTRN12606000510549
|
|
|
ANZ 8811 - A Phase III study to compare the effect of Zoladex depot (ICI 118,630) with Nolvadex plus Zoladex depot in pre- and peri-menopausal patients with advanced breast cancer.
|
Y
|
ACTRN12606000499583
|
|
|
ANZ 8614 - A phase III randomised trial of mitozantrone versus CMFP (cyclophosphamide, methotrexate, 5-flourouracil, prednisone) in advanced breast cancer – a quality of life study
|
Y
|
ACTRN12607000095460
|
|
|
ANZ 8613 - A Phase III trial to evaluate additional versus substitution endocrine therapy in advanced breast cancer.
|
Y
|
ACTRN12607000096459
|
|
|
IBCSG 35-07 / BIG 1-07 - Study of Letrozole Extension (SOLE). Letrozole in Preventing the Return of Cancer in Postmenopausal Women Who Have Received 4-6 Years of Hormone Therapy for Hormone Receptor-Positive, Lymph Node-Positive, Early-Stage Breast Cancer.
|
Y
|
ACTRN12608000243314
|
|
|
IBCSG 34-05 / SWOG 0230 -
A phase III trial of LHRH analogue administration during chemotherapy to reduce ovarian failure following standard adjuvant chemotherapy in early stage, hormone receptor negative breast cancer.
|
Y
|
ACTRN12606000075583
|
|
|
IBCSG 32-05 / BIG 1-05 - Chemotherapy Adjuvant Study for women at advanced age (CASA)
|
Y
|
ACTRN12606000077561
|
|
|
IBCSG 30-04 / NCIC CTG MA 27 - A phase III trial of exemestane vs anastrozole in postmenopausal women with hormone receptor–positive primary breast cancer.
|
Y
|
ACTRN12605000389606
|
|
|
IBCSG 27-02 / BIG 1-02 -Chemotherapy for Radically Resected Loco-regional relapse
|
Y
|
ACTRN12605000387628
|
|
|
IBCSG 26-02 / BIG 4-02 - Premenopausal Endocrine Responsive Chemotherapy Trial
|
Y
|
ACTRN12605000419662
|
|
|
IBCSG 25-02 / BIG 3-02 - Tamoxifen and Exemestane Trial (TEXT)
|
Y
|
ACTRN12605000418673
|
|
|
IBCSG 24-02 / BIG 2-02 - Suppression of Ovarian Function Trial (SOFT)
|
Y
|
ACTRN12605000416695
|
|
|
IBCSG 23-01 - Sentinel Node Biopsy Trial
|
Y
|
ACTRN12605000360617
|
|
|
IBCSG 22-00 - Maintenance Chemotherapy in Hormone Non-Responsive Breast Cancer
|
Y
|
ACTRN12605000355673
|
|
|
IBCSG 21-99 - Menstrual Cycle and Surgical Treatment of Breast Cancer
|
Y
|
ACTRN12607000065493
|
|
|
IBCSG 20-98 / BIG 2-98 - Adjuvant Treatment for patients with node-positive Breast Cancer of Docetaxel sequentially or in combination with Doxorubicin, followed by CMF vs. Doxorubicin alone or in combination with Cyclophosphamide, followed by CMF. BIG 2-98
|
Y
|
ACTRN12606000529549
|
|
|
IBCSG 18-98 / BIG 1-98 - A phase III trial testing letrozole (Femara) against tamoxifen in postmenopausal women with operable breast cancers which are sensitive to oestrogen.
|
Y
|
ACTRN12607000012471
|
|
|
IBCSG 17-98 / BIG 3-97 (HABITS) -
Hormonal replacement therapy after breast cancer diagnosis - is it safe?
|
Y
|
ACTRN12607000038493
|
|
|
IBCSG 16-98 / Intergroup Exemestane Study (IES) - Protocol evaluating postmenopausal women with primary breast cancer who have received adjuvant tamoxifen for two - three years, compared with subsequent treatment using either further tamoxifen or exemestane.
|
Y
|
ACTRN12607000033448
|
|
|
IBCSG 15-95 - Randomised trial of high-dose epirubicin and cyclophosphamide x 3 supported by peripheral blood progenitor cells versus anthracycline and cyclophosphamide x 4 followed by cyclophosphamide, methotrexate, and 5-fluoruracil x 3 as adjuvant treatment for high risk operable stage II and stage III breast cancer in premenopausal and young postmenopausal (<=65 yrs) patients
|
Y
|
ACTRN12607000025437
|
|
|
IBCSG 14-93 - Adjuvant therapy for post/peri menopausal patients with node positive breast cancer who are not suitable for endocrine therapy alone
|
Y
|
ACTRN12607000034437
|
|
|
IBCSG 13-93 - Adjuvant therapy for premenopausal patients with node positive breast cancer who are not suitable for endocrine therapy alone
|
Y
|
ACTRN12607000035426
|
|
|
IBCSG 12-93 - Adjuvant therapy for post/perimenopausal patients with node positive breast cancer who have oestrogen receptor positive tumours
|
Y
|
ACTRN12606000532505
|
|
|
IBCSG 11-93 - Adjuvant therapy for premenopausal patients with node positive breast cancer who are suitable for endocrine therapy alone
|
Y
|
ACTRN12606000534583
|
|
|
IBCSG 10-93 - Surgical therapy with or without axillary node clearance for breast cancer in the elderly who receive adjuvant therapy with Tamoxifen
|
Y
|
ACTRN12607000024448
|
|
|
IBCSG IX - Adjuvant therapy in postmenopausal patients with node negative breast cancer
|
Y
|
ACTRN12607000029493
|
|
|
IBCSG VIII - Adjuvant therapy in pre- and peri-menopausal patients with node negative breast cancer
|
Y
|
ACTRN12607000037404
|
|
|
IBCSG VII - Adjuvant chemotherapy in node positive postmenopausal breast cancer patients: endocrine vs. chemo-endocrine vs. chemo-endocrine with delayed chemotherapy.
|
Y
|
ACTRN12607000023459
|
|
|
ANZUP
|
|
|
|
|
EVERSUN
|
Y
|
ACTRN12609000643279
|
30/07/2009
|
|
SORCE
|
Y
|
ACTRN12609000048280
|
21/01/2009
|
|
Aprepitant Trial
|
Y
|
ACTRN12608000254392
|
20/05/2008
|
|
COGNO
|
|
|
|
|
Phase II - Trial of Temozolomide and Caelyx in the Treatment of Patients with Glioblastoma Multiforme following recurrent radiotherapy and chemotherapy to improve six month progression free survival
|
Y
|
ACTRN12607000090415
|
|
|
TROG
|
|
|
|
|
TROG 06.01 - Primary chemotherapy with Temozolomide versus Radiotherapy in Patients with Low Grade Gliomas After Stratification for Genetic 1p Loss: A Phase III Study to demonstrate a difference in progression free survival.
|
Y
|
ACTRN12607000427471
|
|
|
Phase III - Trial on Concurrent and Adjuvant Temozolomide chemotherapy in non-!p/19q non deleted anaplastic glioma. The CATNON Intergroup Trial
|
|
ACTRN12607000427471/NCT00182819
|
|
|
TROG 08.02 - A Randomized Phase III Study of Temozolomide and Short-Course Radiation versus Short-Course Radiation alone in the treatment of newly diagnosed Glioblastoma Multiforme in elderly patients.
|
|
NCT00482677
|
|
